Skip to NavigationSkip to content

Gilead to lay off one fifth of sales force

Published on 11/04/19 at 10:00am

Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents on two of the company’s older drugs.

Gilead will lay off around 150 cardiopulmonary sales representatives as generic versions of the firm’s heart drugs, Letairis and Ranexa, are set to hit the market.

While Letairis and Ranexa brought in $943 million and $758 million, respectively, in 2018 – Ranexa’s patent expires next month while multiple generics have already been approved for Letairis.

The two drugs generated around 8% of Gilead’s overall sales.

In total Gilead has 11,000 employees. The redundancy of 150 tenured sales people has been described as a cost cutting move.  

The decision was first put into motion almost two years ago, according to BioCentury.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches